Evidence map›Paper›PMID 38818118›Full record

ReviewBioengineering & translational medicine2024

Growth factors and growth factor gene therapies for treating chronic wounds.

James A Mullin, Erfan Rahmani, Kristi L Kiick, Millicent O Sullivan

Abstract readReview
In one paragraph

Review in Bioengineering & translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Exploring New Horizons in Wound Healing: A Comprehensive Analysis.Recent advances in inflammation & allergy drug discovery · 2026
    Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Gene Therapies in Dermatological Diseases: A Breakthrough in Treatment.International journal of molecular sciences · 2025
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

James A MullinDepartment of Chemical and Biomolecular Engineering University of Delaware Newark Delaware USA.ORCID https://orcid.org/0000-0001-8294-2154
Erfan RahmaniDepartment of Biomedical Engineering University of Delaware Newark Delaware USA.
Kristi L KiickDepartment of Biomedical Engineering University of Delaware Newark Delaware USA.
Millicent O SullivanDepartment of Chemical and Biomolecular Engineering University of Delaware Newark Delaware USA.

Funding

Chemistry-Biology Interface Predoctoral Training Grant 2024-2029T32GM133395 · NIGMS · UNIVERSITY OF DELAWARE · PI Catherine Leimkuhler Grimes · 2019 to 2026
$3.7M
COATs: Collagen-mimetic peptide and therapeutic gene-modified collagens for cell-mediated healing of diabetic foot ulcersR01DK130662 · NIDDK · UNIVERSITY OF DELAWARE · PI KIICK, KRISTI L, MARGOLIS, DAVID JOEL · 2021 to 2025
$2.6M
Collagen turnover-stimulated gene delivery to enhance chronic wound repairR01AR067247 · NIAMS · UNIVERSITY OF DELAWARE · PI KIICK, KRISTI L, MARGOLIS, DAVID · 2016 to 2019
$1.4M
NIAMS NIH HHS R01 AR067247NIDDK NIH HHS R01 DK130662NIGMS NIH HHS T32 GM133395
6 · The paper itself

Abstract

Chronic wounds are an unmet clinical need affecting millions of patients globally, and current standards of care fail to consistently promote complete wound closure and prevent recurrence. Disruptions in growth factor signaling, a hallmark of chronic wounds, have led researchers to pursue growth factor therapies as potential supplements to standards of care. Initial studies delivering growth factors in protein form showed promise, with a few formulations reaching clinical trials and one obtaining clinical approval. However, protein-form growth factors are limited by instability and off-target effects. Gene therapy offers an alternative approach to deliver growth factors to the chronic wound environment, but safety concerns surrounding gene therapy as well as efficacy challenges in the gene delivery process have prevented clinical translation. Current growth factor delivery and gene therapy approaches have primarily used single growth factor formulations, but recent efforts have aimed to develop multi-growth factor approaches that are better suited to address growth factor insufficiencies in the chronic wound environment, and these strategies have demonstrated improved efficacy in preclinical studies. This review provides an overview of chronic wound healing, emphasizing the need and potential for growth factor therapies. It includes a summary of current standards of care, recent advances in growth factor, cell-based, and gene therapy approaches, and future perspectives for multi-growth factor therapeutics.

Indexed as

chronic woundsgene therapygrowth factors

Identifiers

PMID38818118
PMCPMC11135157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.